QT
URGN icon

Quantamental Technologies’s UroGen Pharma URGN Stock Holding History

Quantamental Technologies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,400
Closed -$81K – 1300
2019
Q3 		$81K Buy
3,400
+3,034
+829% +$99.2K 0.03% 809
2019
Q2 		$13K Sell
366
-34
-9% -$1.25K ﹤0.01% 1209
2019
Q1 		$15K Buy
400
+100
+33% +$4.19K 0.01% 1168
2018
Q4 		$13K Buy
+300
New +$13.5K 0.01% 1106

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantamental Technologies's URGN Position: Q4 2019 in Review

Quantamental Technologies sold out of UroGen Pharma (URGN) in Q4 2019, closing a stake of 3,400 shares — an estimated $81K sold.

Quantamental Technologies first reported a position in URGN in Q4 2018 and held it in 4 quarters. The position peaked at $81K in Q3 2019. 86 funds tracked by Wall St. Rank hold URGN as of Q4 2019.

  • Quantamental Technologies reported no remaining UroGen Pharma position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 3,400 UroGen Pharma shares in Q4 2019, an estimated $81K.
  • Quantamental Technologies first reported a position in UroGen Pharma in Q4 2018 and held it in 4 quarters.
  • Quantamental Technologies's UroGen Pharma position peaked at $81K in Q3 2019.
  • 86 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.